Daily Chart

Popular Trending Tickers


Ticker Sitemap
Will BMY go up?

Send a Tweet

$BMY
#Bristol-Myers Squibb
BMY
Bristol-Myers Squibb
Look for:
BMY
Todays recommendations include $BMY and $DBTK, to find out more sign up for the Free Daily Newsletter from the... http://bit.ly/ckd39a
BMY
$BMY (Bristol-Myers Squibb) $24.23 crossed its 1st Pivot Point Resistance #emppv #stocks http://empirasign.com/l/tx2d.htm
BMY
Continue to think $MJD could be acquisition target. Recently spun off by $BMY in tax advantaged structure. Potential set up for a sale $$
BMY
Stopped out of $BMY, $JCG, $GS, and $WLT. Today is like an entire reset to my portfolio!
BMY
RT @mhuckman Blogging about "Cherish Bio Sciences" and revealing my own "corporate secret." $BMY http://bit.ly/ahpm9G
BMY
Blogging about "Cherish Bio Sciences" and revealing my own "corporate secret." $BMY http://bit.ly/ahpm9G
BMY
RT @mhuckman: US Atty says guy worked in Bristol tech ops & stole "numerous trade secrets" from '07 until he was fired yesterd
BMY
RT @adamfeuerstein: My story on $ALKS and its 1x/ mo. version of $BMY's Abilify. http://bit.ly/cyv92V hey @popsalks, what do you think?
BMY
RT @adamfeuerstein: My story on $ALKS and its 1x/ mo. version of $BMY's Abilify. http://bit.ly/cyv92V hey @popsalks, what do you think?
BMY
My story on $ALKS and its 1x/ mo. version of $BMY's Abilify. http://bit.ly/cyv92V hey @popsalks, what do you think?
BMY
Alkermes $ALKS PR on very early-stage development for potential 1x/mo version of Bristol's Abilify. $BMY http://tinyurl.com/pmalksabil
BMY
Cherish JAIL Time, Boy RT @mhuckman Bristol $BMY guy charged w/stealing co secrets was.. planning to start a drug, "Cherish Bio Science
BMY
RT @mhuckman: Reading feds' criminal complaint against $BMY Bristol employee charged with stealing trade secrets to start a rival drug firm
BMY
I'm not a techie. But fed complaint says Bristol guy was loading confidential $BMY docs onto removable external hard drives from his laptop.
BMY
Bristol $BMY guy charged w/stealing co secrets was said 2 b planning to start a drug co called "Cherish Bio Sciences" in India w/h
BMY
Alleged stolen $BMY docs from E. Syracuse plant incl part of recipe for a biologic, how 2 handle FDA inspection & investigate bad sample
BMY
Reading feds' criminal complaint against $BMY Bristol employee charged with stealing trade secrets to start a rival drug firm in India.
BMY
RT @mhuckman: US Atty charges Syracuse man w stealing trade secrets from employer Bristol-Myers Squibb $BMY to try to start a drug co in his
BMY
US Atty says guy worked in Bristol tech ops & stole "numerous trade secrets" from '07 until he was fired yesterday. $BMY
BMY
RT @mhuckman: Separately, Bristol-Myers Squibb says no pay raises this year. $BMY
BMY
Separately, Bristol-Myers Squibb says no pay raises this year. $BMY
BMY
RT @mhuckman: US Atty charges Syracuse man w stealing trade secrets from employer $BMY to try to start a drug co in his native India.
BMY
US Atty charges Syracuse man w stealing trade secrets from employer Bristol-Myers Squibb $BMY to try to start a drug co in his native India.
BMY
$BMY (Bristol-Myers Squibb) $24.75 crossed its 1st Pivot Point Resistance #emppv #stocks http://empirasign.com/l/a2m.htm
BMY
RT @bradfranklin - RT @mhuckman: Barron's: On the NYSE Bristol-Myers Squibb $BMY had biggest short interest fall. Down 30%.
BMY
RT @mhuckman: Barron's: On the NYSE Bristol-Myers Squibb $BMY had biggest short interest fall. Down 30%.
BMY
Barron's: On the NYSE Bristol-Myers Squibb $BMY had biggest short interest fall. Down 30%.
BMY
anyone know if this $BMY warning letter is good for $GILD? ($GILD starting to move now)

Bristol-Myers Squibb Co. - BMY Insiders

No Insiders

We have no insiders for Bristol-Myers Squibb right now.

Know someone who is an insider on Bristol-Myers Squibb Co.?
Let us know.

Bristol-Myers Squibb Co. - BMY information

Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York....
www.bms.com
28,000 Employees
Founded in 1887

BRISTOL-MYERS SQUIBB CO (BMY:New York)

LAST $26.46 USD
CHANGE TODAY +0.03 0.11%
VOLUME 1.1M
As of 10:03 AM 09/3/10 All times are local (Market data is delayed by at least 15 minutes).

Snapshot of BRISTOL-MYERS SQUIBB CO (BMY)

OPEN
$26.46
PREVIOUS CLOSE
$26.43
DAY HIGH
$26.55
DAY LOW
$26.38
52 WEEK HIGH
03/29/10 - $27.07
52 WEEK LOW
09/3/09 - $21.54
MARKET CAP
45.4B
AVERAGE VOLUME 10 D
11.1M
EPS TTM
$2.08
SHARES OUTSTANDING
1.7B
EX-DATE
06/30/10
P/E TTM
12.7x
DIVIDEND
$1.28
DIVIDEND YIELD
4.81%
K = Thousands  M = Millions  B = Billions

related news

*Jefferies analyst upgrades Bristol-Myers to "Buy"
BMY: Upgrade - JAGNote by Jefferies & Company, Inc.
BMY: Upgrade - JAGNote by Jefferies & Company, Inc.
*AstraZeneca says blood thinner met key study goals
[addPosition2]

Key developments for BRISTOL-MYERS SQUIBB CO (BMY)

Bristol-Myers Squibb Company and Pfizer Inc. Evaluate Unmet Need in Patients with Atrial Fibrillation

Bristol-Myers Squibb Company and Pfizer report that preliminary results from the Phase 3 clinical trial of the investigational drug apixaban compared with acetylsalicylic acid in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2010. The results will be presented during the Hot Line session on August 31, 2010, in Stockholm Sweden. Atrial fibrillation is the most common serious chronic arrhythmia, affecting about 4.5 million people in Europe and 2.2 million people in the United States. Patients with AF are at five times greater risk for stroke compared with the general population. 15% of all strokes are attributable to AF, and one quarter of all strokes in persons older than 80 years are attributable to AF. In addition to treatments for heart rate and rhythm, treatment guidelines recommend that AF patients at moderate to high risk of stroke receive anticoagulation therapy with a vitamin K antagonist (VKA), such as warfarin. However, surveys of practice patterns in developed countries demonstrate that 40% to 50% of patients with AF who are at moderate or high risk for stroke do not receive VKA. The most common reason for not treating AF patients with a VKA appears to be concern about bleeding. Difficulties managing and maintaining therapeutic warfarin dosing, as well as the use of other prescription drugs that interfere with warfarin therapy are additional concerns. Currently, guidelines for the management of patients with AF recommend the use of aspirin for those who cannot take oral anticoagulants.

Bristol-Myers Squibb Company's Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated. The company also announced that the application has been granted a priority review designation by the FDA. Ipilimumab is Bristol-Myers Squibb's second drug under priority review by the FDA this year. A priority review designation is granted to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. Based on FDA's six month goal for completing priority reviews, the projected FDA action date is December 25, 2010. The filing is based on results from the primary analysis of the pivotal MDX010-020 trial, which were published online in the New England Journal of Medicine and presented during a plenary session at the 46th Annual Meeting of the American Society of Clinical Oncology in June 2010. The study compared the overall survival rate of patients who received ipilimumab plus the gp100 vaccine (3 mg/kg and 1mg/kg every three weeks for four doses; n=403), ipilimumab alone (3 mg/kg every three weeks for four doses; n=137) and the control therapy of gp100 alone (n=136). Ipilimumab is also currently under review with the European Medicines Agency (EMA) and other health authorities for the treatment of adult patients with previously treated advanced melanoma.

Bristol-Myers Squibb Company Announces belatacept

Bristol-Myers Squibb Company announced that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of seven oral clinical presentations related to kidney transplantation at the 23rd International Congress of The Transplantation Society, being held August 15--19, 2010, in Vancouver, British Columbia, Canada. In total, 18 abstracts from company-sponsored studies will be presented during the congress. Belatacept is currently under review with the U.S. Food and Drug Administration (FDA), as well as the European Medicines Agency (EMA) and other health authorities, for use in adult patients receiving kidney transplants. On May 1, 2010, Bristol-Myers Squibb received a complete response letter from the FDA requesting 36-month data from the ongoing Phase 3 studies to further evaluate the long-term effect of belatacept. The company is working with the FDA to provide that data, as well as answer some requests for information to support the manufacturing of belatacept and the proposed Risk Evaluation and Mitigation Strategy (REMS) program.

BMY Competitors

Company Last Change
3M Co $83.55 USD +1.68
Amgen Inc $52.97 USD +0.4613
Eli Lilly & Co $34.55 USD +0.24
Takeda Pharmaceutical Co Ltd ¥3,930 JPY +40.00
Teva Pharmaceutical Industries Ltd $51.78 USD +0.267
Market data is delayed at least 15 minutes.
 

Industry Analysis

Valuation BMY Industry Range
Price/Earnings 14.9x
Price/Sales 2.3x
Price/Book 2.9x
Price/Cash Flow 4.3x
TEV/Sales 1.6x

BMY

 | 

BMY transactions

Type
Date
Target
Merger/Acquisition
July 7, 2010
Bristol-Myers Squibb Company, Medical Preparations and Rights
Buyback
May 4, 2010
--
Merger/Acquisition
March 29, 2010
Bristol-Myers Squibb Company, Sermoneta Facility

Bristol-Myers Squibb Co. - BMY news

A.M. Vitals: Genzyme Says Sanofi Needs to Cough Up More Cash

Quote: At least four other drugs are also in development, including one by Bristol-Myers Squibb and Pfizer that was also the subject of a positive study released at the meeting. Dialysis DealNYT reportssubsequent litigation over whether undocumented immigrants deserve life-saving care, the paper says. Stem Cell Requestblocked government fundingWSJ reports. The Justice Department says the ruling jeopardizes ongoing experiments, some of which were funded under Bush administration guidelines. Image: iStoc...
Read article

15 Dividend-Paying Rally Stocks With Attractive Valuations

Quote: Bristol-Myers Squibb Company (BMY): Drug Manufacturer. Dividend yield of 4.91%, with a current ratio of 2.2. TTM P/E ratio at 14.24 vs. the industy avg. at 43.13. TTM P/S ratio at 2.31 vs. the industry avg. at 2.61. The stock has gained 24.01% over the last year.3. Novartis AG (NVS): Drug Manufacturer. Dividend yield of 3.71%, with a current ratio of 2.17. TTM P/E ratio at 12.31 vs. the industy avg. at 42.55. TTM P/S ratio at 2.46 vs. the industry avg. at 2.61. The stock has gained 17.14% over t...
Read article

Croatian seamstress in $2.83 mln accord with SEC

Keywords: United States,Banking Services,Financials,Banks,Financials,Lawmaking,Judicial Process / Court Cases / Court Decisions,Regulations / Standards,Investment Banking and Brokerage Services,Funds,Crime,Biotechnology / Pharmaceuticals,Europe,South Korea,Cameroon
Quote: Prosecutors said the ring traded on leaks about mergers, market-moving media reports and a grand jury probe involving the drugmaker Bristol-Myers Squibb Co (BMY.N). People who leaked information included a Merrill Lynch & Co analyst, workers at a printing plant for BusinessWeek magazine, and a New Jersey postal worker who sat on the grand jury. The case is SEC v. Anticevic et al, U.S. District Court, Southern District of New York, No. 05-06991.(Reporting by Jonathan Stempel in New York; edit...
Read article

Bayer and Bristol's rival clot drugs both impress

Keywords: Pharmaceuticals - Diversified,Biotechnology / Pharmaceuticals,United States,Sweden,Germany,Western Europe,Europe,Chemicals,Healthcare,Pharmaceuticals,Pharmaceuticals / Medical Research,Nordic States,Company News item,Economic news, EC, business/financial
Quote: Tue Aug 31, 2010 5:16am EDT * Bristol/Pfizer's apixaban cuts stroke by half vs aspirin * Bayer/J&J's Xarelto shows reassuring safety profile * Both racing to replace old, difficult-to-use drug warfarin * Bayer shares up 1.9 percent in lower market(Wraps trial results on Bayer's Xarelto, Bristol's apixaban) By Ben Hirschler STOCKHOLM, Aug 31 (Reuters) - Rival anti-clotting drugs from Bayer (BAYGn.DE) and Bristol-Myers Squibb (BMY.N) both impressed in clinical trials, keeping them firmly in t...
Read article

Astra's Brilinta wins early backing in guidelines

Keywords: Pharmaceuticals - Generic / Specialty,Biotechnology / Pharmaceuticals,United Kingdom,Western Europe,Europe,Pharmaceuticals - Diversified,France,United States,Sweden,Healthcare,Pharmaceuticals,Pharmaceuticals / Medical Research,Company News item,Economic n
Quote: Brilinta is being assessed by regulators in Europe, following positive clinical trial results a year ago, which found it was superior to Plavix, the standard treatment made by Sanofi-Aventis (SASY.PA) and Bristol-Myers Squibb's (BMY.N). It is expected to win a green light to go on sale in the United States as early as next month, after being endorsed by a U.S. advisory panel last month. [ID:nN28178213](Reporting by Ben Hirschler; Editing by David Cowell)......
Read article

A.M. Vitals: Genzyme Rejects Takeover Offer From Sanofi-Aventis

Quote: The CBO : Data presented at a cardiology meeting in Stockholm suggest that a genetic test can’t effectively predict who will benefit from the blood thinner Plavix, co-marketed by Sanofi-Aventis and Bristol-Myers Squibb, the . One study showed that AstraZeneca’s experimental drug Brilinta — : The American Academy of Pediatrics is calling for a reduction in inappropriate sexual messages in the media, including the restriction of erectile dysfunction drug ads to 10pm or later, the...
Read article

The Cancer Trial Bristol and Roche Must Do Now

Quote: Almost nothing worked.Ipilimumab from Bristol-Myers SquibbJames Allison,boosted patient survival by three months, a big trial found. 80% of melanoma patientsmatter of months. It has not been proven to extend how long patients live. GlaxoSmithkline is testing a similar drug. almost miraculous. Dead tissue produced by the anti-tumor effects of the Roche drug, could help stimulate the immune system and enhance the impact of the Bristol drug.  In test tube experiments, blocking BRAF protein in me...
Read article

Thursday Options Brief: CVBF, PFG, SCHW & BMY

Quote: Bristol-Myers Squibb Co.(BMY) – The pharmaceutical company’s shares are down 0.85% to stand at $25.86 as of 12:05 pm ET, but it looks like a number of options investors are betting on a near-term rebound in the price of the underlying stock. Optimists purchased approximately 6,000 calls at the September $27 strike for an average premium of $0.25 apiece. It looks like today’s call buyers are adding to long call open interest at that strike initiated by like-minded traders who pi...
Read article

Bristol-Myers Squibb and Pfizer Inc Evaluate Unmet Need in Patients with Atrial Fibrillation

Keywords: Bristol-Myers Squibb and Pfizer Inc Evaluate Unmet Need in Patients with Atrial Fibrillation, bmy,pfe
Quote: The results will be presented during the “Hot Line”session on August 31, 2010, in Stockholm, Sweden.12111113About the Bristol-Myers Squibb/Pfizer CollaborationIn 2007, Pfizer and Bristol-Myers Squibb entered into a worldwidecollaboration to develop and commercialize apixaban, an investigationaloral anticoagulant discovered by Bristol-Myers Squibb. This globalalliance combines Bristol-Myers Squibb's long-standing strengths incardiovascular drug development and commercialization with P...
Read article

Roche melanoma drug works in 81 pct of patients

Keywords: Pharmaceuticals - Diversified,Biotechnology / Pharmaceuticals,Switzerland,Western Europe,Europe,United States,Health / Medicine,Regulations / Standards,Healthcare,Pharmaceuticals,Pharmaceuticals / Medical Research,Central/Eastern Europe,Company News item,
Quote:
Read article

PREVIEW-Battle of anticoagulants to dominate heart meeting

Keywords: Pharmaceuticals - Diversified,Chemicals,Germany,Western Europe,Europe,Biotechnology / Pharmaceuticals,United States,Japan,Sweden,Healthcare,Pharmaceuticals,Pharmaceuticals / Medical Research,Central/Eastern Europe,Eurozone countries,Company News item,Econ
Quote: Tue Aug 24, 2010 8:09am EDT* Data on Bayer's Xarelto, Bristol's apixaban due on Aug 31 * Both drugs chasing Pradaxa as alternatives to warfarin * Warfarin replacement market seen more than $10 billion/yr * Experts to focus on bleeding risks with rival treatments By Ben Hirschler, European Pharmaceuticals Correspondent LONDON, Aug 24 (Reuters) - Rival anti-clotting pills being developed by Bayer (BAYGn.DE) and Bristol-Myers Squibb (BMY.N) are both set to show positive results next week as the ra...
Read article

Eli Lilly Failure Could Pave Way For New Alzheimers Approach

Quote: made patients worseputs a question mark over prospects for similar drugs in testing at Bristol-Myers Squibb, Pfizer, Elan and elsewhere. skeptical all alongmy recent article: Adds Merck Vice President Richard Hargreaves: “There has been a sort of a narrow-minded approach to Alzheimer’s disease. Amyloid deposition is only one of the features.” A New Look At Alzheimer’s – Forbes.com. Here are some of the approaches scientists at Pfizer and Bristol-Myers Squibb and els...
Read article

Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma

Keywords: Ipilimumab Receives FDA Priority Review Designation for Adult Patients with Previously Treated Advanced Melanoma, bmy
Quote: Food andDrug Administration (FDA) has accepted, for filing and review, theBiologics License Application (BLA) for ipilimumab for the treatment ofadult patients with advanced melanoma who have been previously treated.The company also announced today that the application has been granted apriority review designation by the FDA.Ipilimumab is Bristol-Myers Squibb's second drug under priority reviewby the FDA this year. A priority review designation is granted to drugsthat offer major advances in tre...
Read article

Eli Lilly Alzheimers Failure Bolsters Skeptics on Amyloid Theory

Quote: Eli Lilly, Pfizer, Elan, Bristol-Myers Squibb and other drug companies have been rushing to test drugs that block the protein deposits found in the brain of Alzheimer’s Disease patients called amyloid. The theory is that these amyloid plaques kill brain cells, and that removing them with a drug–or their growth–will halt dementia. skepticsit made the disease worse in tests on 2600 patients. The company released few other details, other than to say the drug also increased the ris...
Read article

Data on Investigational Drug Belatacept in Kidney Transplant Recipients to Be Presented at 23rd International Congress of The Transplantation Society

Keywords: Data on Investigational Drug Belatacept in Kidney Transplant Recipients to Be Presented at 23rd International Congress of The Transplantation Society, bmy
Quote: of CaliforniaSan Francisco, CAAbout BelataceptBelatacept is an investigational agent under development byBristol-Myers Squibb for the prophylaxis of organ rejection in adultpatients receiving kidney transplants. The proposed trade name forbelatacept is NULOJIXâ„¢.Belatacept is a fusion protein designed to be a selective T cellco-stimulation blocker that binds to a specific site on certain cells ofthe immune system (i.e., antigen presenting cells) to block the secondsignal necessary to activa...
Read article

Bristol-Myers Squibb and ADAP Crisis Task Force Announce Enhanced, Multi-year Support for AIDS Drug Assistance Programs (ADAPs) in the United States

Keywords: Bristol-Myers Squibb and ADAP Crisis Task Force Announce Enhanced, Multi-year Support for AIDS Drug Assistance Programs (ADAPs) in the United States, bmy
Quote: “We commend Bristol-Myers Squibb forresponding to the unprecedented need faced by state ADAPs to provideaccess to HIV medicines and enhance our March agreement by providingadditional support. Our long working relationship with Bristol-MyersSquibb made this agreement possible.”“Ensuring access to treatment for HIV and AIDS requires the commitmentand participation of government, industry and the community,” said LyndaDee of AIDS Action Baltimore and member of the Fair Prici...
Read article

Exelixis cuts Q2 loss to $22.6M

Quote: on Thursday reported a second quarter loss of $22.6 million, or 21 cents a share, halved from a loss in the same quarter last year of $44.8 million, or 42 cents a share.The South San Francisco-based biotech (NASDAQ:EXEL) had revenue of $47.6 million, up from the year-ago quarter's $27.4 million.Research and development expenses for the quarter were $54.2 million, down slightly from $55 million in the same period last year.The increase was primarily due to revenue from collaborations with San...
Read article

Three Stocks That Can Survive a Bear Market

Quote: Bristol-Myers Squibb (NYSE: BMY) Shares of this large drug maker didn't fall very much when stocks were tanking in early 2009 thanks to a strong balance sheet, boringly predictable revenue streams and a juicy dividend yield.These days, the company remains a bit boring -- sales grew +2% in themost recent quarter -- and investors are so indifferent that sharesoffer a hefty 5% dividend yield. Yet Bristol-Myers Squibb's financialfirepower is so strong that the company is also conducting a $3 billion...
Read article

RPT-UPDATE - Bayer, J&J eye mass market after Xarelto study

Keywords: Germany,Western Europe,Europe,Pharmaceuticals (sub-industry),Chemicals,Health and medicine,Regulation and enforcement,United States of America,Pharmaceuticals - diversified,Japan,Asia,Central and Eastern Europe,General News,Nature Society and Science,Busi
Quote:
Read article

AstraZeneca 2Q profit up 22 pct

Keywords: AstraZeneca 2Q profit up 22 pct, azn,bmy,pfe,san, earnings
Quote: patients studied were more likely to report heart problems while taking Brilinta.AstraZeneca needs Brilinta to help fill a gap in its drugs pipeline as revenue from both Seroquel and Nexium -- which had flat sales of $1.26 billion in the quarter -- are hurt by generic competition.The blood thinner market is currently dominated by Sanofi-Aventis SA and Bristol-Myers Squibb Co.'s blockbuster drug Plavix. With global sales of $9.1 billion in 2009, Plavix was the world's second-best selling drug beh...
Read article
Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.